AMLX ▾TradingViewOVTLYR consoleNews (1w)Earnings search — Amylyx Pharmaceuticals, Inc.

Healthcare · ETF XLV · as of 2026-09-23

Daily · EMA 10 / 20 / 50 · SMA 200 · VolPress: buy/sell split, 20-SMA, white dot = above avg · · E = earnings · RS vs SPY ⓘ · ● RS new high ⓘ
AMLX
Amylyx Pharmaceuticals, Inc. NMS
Healthcare · Drug Manufacturers - Specialty & Generic

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.

Market cap
2.5B
P/E (TTM)
-
EPS (TTM)
-1.41
Employees
136
IPO
2022-01-07
Website
amylyx.com

Price & today

$30.61 ATR(14) 1.84 (6.02%)
Stock today-7.26%
Sector ETF today-0.64%
Residual (stock-specific)-6.62%

Sector correlation

20-day correlation with XLV0.42
60-day correlation with XLV0.25
Status normal

Decoupling fires when 60d corr − 20d corr > 0.20: stock used to track its sector but the relationship has weakened recently.

Technicals

10 EMA$32.56
20 EMA$32.37
50 EMA$28.70
EMA stackBULLISH
RSI(14)46.2
52-week high distance+24.41%
52-week low distance+302.17%

Signals

Market F&G44.9
Bull%13.8%
OVTLYR status SELL (14d)
Sector rank#487
Next earnings 2026-11-04 (TNS, 41d)
TradingView OVTLYR console More news (Google) Sector dashboard (XLV)

MarketSmith metrics - our compute

RS Rating
94.2
ADR%
5.1
RMV (tight)
69.0
Ext (ATR>20EMA)
-1.0
Rel Vol
70.0%
U/D 50d
1.45
U/D 25d
0.86
Accum/Dist 25d
2 / 4
EPS YoY
+15.0%
LoD dist
4.0
Off 52w High
25.6%
Above 52w Low
182.6%
1W / 1M
-6.2 / -19.8
Avg $Vol 50d
79.6M
Mkt Cap (B)
3.4
Trend 8/8
no
Leads Group
YES
Sector XLV
+0.6% 1W
Base len (VCP)
13wk (4/24)
Coil (base shape)
85TVPX
What do these abbreviations mean?
RS Rating
- IBD-style relative strength vs SPY (weighted 3/6/9/12-mo). 70+ = leaders pool, 80+ = strong.
ADR%
- average daily range over 20 days. 4%+ = the fast movers the playbook prefers (selection order, not a gate).
RMV (tight)
- Relative Measured Volatility, 15 bars, scaled 0-100. <15 = tight coiled base (green), <35 moderate, high = loose/expanding - not a base right now.
Ext (ATR>20EMA)
- how many ATRs price sits above its 20-EMA. ≤1 = in value (green), >2 = extended/chasing (red) - prefer a pullback.
Rel Vol
- latest volume vs the 50-day average. 100% = normal; 140%+ = breakout confirmation.
U/D 50d / 25d
- up-day vs down-day volume over the window. 1.1+ = net accumulation (institutions buying); under 0.9 on the 25d = net selling.
Accum/Dist 25d
- heavy-volume up days vs heavy-volume down days in the last 25 sessions (close moved 0.2%+ on above-average volume). The institutional-participation footprint; 5+ distribution days = O'Neil caution line.
LoD dist
- close distance above the day low in % of ATR (100 = one full ATR off the low). High = strong close.
Off/Above 52w
- trend-template legs: within 25% of the 52-week high, at least 25% above the 52-week low.
Trend 8/8
- all 8 Minervini Trend Template criteria pass. Discovery floor, NOT an entry signal - entries come from the VCP pivot.
Base len (VCP)
- weeks since the VCP base started on the latest scan. 10wk+ bases carry the edge; short stacked bases test below random.

Fundamentals & valuation - reference, not entry inputs

P/E (TTM)
-
Fwd P/E
-
PEG
-
Price/Book
10.6
Profit margin
0.0%
ROE
-74.7%
Debt/Equity
2.2
Rev growth
-
Analyst target
$28 (-7%)
Analyst rating
STRONG_BUY
Institutional %
105.9%
Insider %
7.9%
Float %
73.8%
Valuation and analyst figures are Yahoo company stats (weekly refresh, ~3,000 larger names - blanks are honest gaps); logo, employees, website and IPO date are Massive company reference. Momentum/VCP entries do not use valuation - this card is context so you do not have to leave the page.

Company data - context read, not entry inputs

Industry rank
30 / 146
Industry
Drug Manufacturers - Specialty & Generic
Float
82.0M
Float turnover 20d
2.1%
Avg $Vol 20d / 50d
57.3M / 79.6M
Days to cover
6.9
Short % float
14.3%
Institutional %
105.9%
Weinstein stage
2
Float, short interest and institutional % come from Yahoo company stats, refreshed weekly for ~3,000 larger names - a blank means Yahoo does not publish the figure for this stock, not that it is zero. Dollar volume and float turnover are computed from our own price bars; industry rank from our rotation data; stage from the weekly chart.

Quarterly EPS - earnings acceleration

A dash in %Chg is deliberate: the year-ago figure was a loss, so a growth % would be meaningless. A dash in Sales means we have no revenue figure for that quarter - read it as a gap in our data, not as zero revenue.

QuarterEPS ($)%Chg YoYSales ($M)%Chg
Nov-24 -1.07 -457% 0.4 -100%
Mar-25 -0.55 -886% - -
May-25 -0.42 - 0.0 -100%
Aug-25 -0.46 - 0.0 +100%
Nov-25 -0.37 - 0.0 -100%
Mar-26 -0.30 - 0.0 -
May-26 -0.37 - - -
Aug-26 -0.39 - - -
† = SEC carries this same fiscal quarter under a second period-end with a materially different figure (hover for it) - a restatement, merger recast or successor-period split; %Chg is blanked when the two are more than 15% apart. It fires only when the two period-ends DISAGREE, so it is a floor, not a guarantee that the rest of the column shares one basis · ‡ = the revenue concept changed from the previous quarter WITH A FIGURE (hover for both) - a blank row in between is skipped, as the eye does - a step at that row is a change of basis, not necessarily of business · EPS = Yahoo eps_actual (the figure MarketSmith/Deepvue show) - whether a given quarter is GAAP or excludes a one-off follows the filing, so it can sit either side of another vendor's number; AAPL's Oct-24 row, the Sep-2024 fiscal quarter, is $0.97 here - GAAP, including the EU tax charge - where TradingView's year implies $1.64 · Sales ($M) = SEC EDGAR quarterly revenue (fiscal Q4 derived as FY minus 9-mo) · quarter = report month · %Chg blank = prior-year base under $0.05 (not meaningful).

Recent news - our DB (Finnhub + OVTLYR)